Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators

Favaloro Foundation, Buenos Aires, Argentina.

OBJECTIVES: We assessed the outcomes of patients with a first myocardial infarction with ST segment elevation, with and without the development of abnormal Q waves after thrombolysis. BACKGROUND: Prethrombolytic era studies report conflicting short-versus long-term mortality in the overall non-Q wave population, probably related to its heterogeneity. METHODS: Patients with no electrocardiographic (ECG) confounding factors or evidence of previous infarction were included. Q wave infarction was defined as a Q wave duration > or = 30 ms in lead aVF; R wave > or = 40 ms in lead V1; any Q wave or R wave < or = 10 ms and < or = 0.1 mV in lead V2; or Q wave > or = 40 ms in at least two of the following leads: I, aVL, V4, V5 or V6. In-hospital clinical events and mortality at 30 days and 1 year were assessed. RESULTS: No Q waves developed in 4,601 (21.3%) of the 21,570 patients. This group comprised more women and had a lower Killip class, lower weight and less anterior baseline ST elevation. The non-Q wave group had less in-hospital cardiogenic shock (2.1% vs. 3.3%, p < 0.0001), less heart failure (8.5% vs. 13.9%, p < 0.0001) and a trend toward less stroke (0.7% vs. 1.0%, p = 0.07) but an increased use of angioplasty (28% vs. 24%, p = 0.0001). The unadjusted mortality rate in the non-Q wave group was lower at 30 days (0.9% vs. 1.8%, p = 0.0001) and 1 year (2.7% vs. 4.2%, p = 0.0001), as was the adjusted 30-day mortality rate (4.8% vs. 5.3%, p < 0.0001). CONCLUSIONS: Patients with no ECG confounding factors or evidence of previous infarction who do not develop Q waves after thrombolysis have a better 30-day and 1-year prognosis than patients with a Q wave infarction.

This article has been cited by other articles:

				A. Halkin, D. Fourey, A. Roth, V. Boyko, and S. Behar Incidence and prognosis of non-Q-wave vs. Q-wave myocardial infarction following catheter-based reperfusion therapy QJM, June 1, 2009; 102(6): 401 - 406. [Abstract] [Full Text] [PDF]

				H. Tomoda and N. Aoki Pathophysiology of Early Coronary Angioplasty with Stenting on Non-Q-Wave vs Q-Wave Myocardial Infarction Angiology, October 1, 2001; 52(10): 671 - 679. [Abstract] [PDF]

				J Abdulla, B Brendorp, C Torp-Pedersen, L Kober, and on behalf of the TRACE study group Does the electrocardiographic presence of Q waves influence the survival of patients with acute myocardial infarction? Eur. Heart J., June 2, 2001; 22(12): 1008 - 1014. [Abstract] [PDF]

				M. I. Furman, H. L. Dauerman, R. J. Goldberg, J. Yarzbeski, D. Lessard, and J. M. Gore Twenty-two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial q-wave and non-q-wave myocardial infarction: a multi-hospital, community-wide perspective J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1571 - 1580. [Abstract] [Full Text] [PDF]

				S Kennon, K Barakat, A Suliman, P K MacCallum, K Ranjadayalan, P Wilkinson, and A D Timmis Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction Heart, July 1, 2000; 84(1): 41 - 45. [Abstract] [Full Text] [PDF]

				A Al-Mohammad, M Y Norton, I R Mahy, J C Patel, A E Welch, P Mikecz, and S Walton Can the surface electrocardiogram be used to predict myocardial viability? Heart, December 1, 1999; 82(6): 663 - 667. [Abstract] [Full Text]

				P. Porela, H. Helenius, K. Pulkki, and L.-M. Voipio-Pulkki Epidemiological classification of acute myocardial infarction: time for a change? Eur. Heart J., October 2, 1999; 20(20): 1459 - 1464. [Abstract] [PDF]

				S. G. Goodman, A. Langer, A. M. Ross, N. M. Wildermann, A. Barbagelata, E. B. Sgarbossa, G. S. Wagner, C. B. Granger, R. M. Califf, E. J. Topol, et al. Non–Q-Wave Versus Q-Wave Myocardial Infarction After Thrombolytic Therapy : Angiographic and Prognostic Insights From the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries–I Angiographic Substudy Circulation, February 10, 1998; 97(5): 444 - 450. [Abstract] [Full Text] [PDF]